Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment

Wei Liang, Maciej Kujawski, Jun Wu, Jianming Lu, Andreas Herrmann, Sofia Loera, Yun Yen, Frank Lee, Hua Yu, Wei Wen, Richard Jove

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: Several Src family kinase (SFK) inhibitors have entered clinical trials based on their direct effects against tumor cells. Here, we characterize the effects of targeting Src kinases on the tumor micro-environment and how these effects influence tumor growth. Experimental Design: Human cancer cells grown in cell culture or in mice were treated with dasatinib, a small-molecule inhibitor of SFKs. Tumor cell, endothelial cell, and myeloid cell compartments within the tumor microenvironment were analyzed. Primary human endothelial cells and freshly isolated CD11b+/CD11c- myeloid cells from mice were treated with dasatinib in cell culture. Cellular functions and signaling pathways affected by dasatinib were evaluated. Results: Dasatinib was not cytotoxic in cell culture against the human cancer cell lines investigated here. However, dasatinib administration in human tumor-bearing mice suppressed tumor growth associated with increased tumor cell apoptosis, decreased microvessel density, and reduced intratumoral CD11b+ myeloid cells. Dasatinib directly inhibited motility and other functions of endothelial and myeloid cells, accompanied by the inhibition of phosphorylation of SFKs and downstream signaling. Tumor-infiltrating myeloid cells were identified as the major source of matrix metalloproteinase (MMP)-9 in the tumor microenvironment. Dasatinib treatment reduced MMP-9 levels in the tumor microenvironment through the simultaneous inhibition of recruitment of MMP9+ myeloid cells and MMP-9 gene expression in tumor-infiltrating myeloid cells. Conclusions: These findings suggest that Src kinase inhibitors such as dasatinib possess a previously unrecognized anticancer mechanism of action by targeting both host-derived endothelial and myeloid cell compartments within the tumor microenvironment.

Original languageEnglish
Pages (from-to)924-935
Number of pages12
JournalClinical Cancer Research
Volume16
Issue number3
DOIs
Publication statusPublished - Feb 1 2010
Externally publishedYes

Fingerprint

Tumor Microenvironment
src-Family Kinases
Myeloid Cells
Endothelial Cells
Neoplasms
Matrix Metalloproteinase 9
Cell Culture Techniques
Dasatinib
Growth
Microvessels
Research Design
Phosphorylation
Clinical Trials
Apoptosis
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment. / Liang, Wei; Kujawski, Maciej; Wu, Jun; Lu, Jianming; Herrmann, Andreas; Loera, Sofia; Yen, Yun; Lee, Frank; Yu, Hua; Wen, Wei; Jove, Richard.

In: Clinical Cancer Research, Vol. 16, No. 3, 01.02.2010, p. 924-935.

Research output: Contribution to journalArticle

Liang, W, Kujawski, M, Wu, J, Lu, J, Herrmann, A, Loera, S, Yen, Y, Lee, F, Yu, H, Wen, W & Jove, R 2010, 'Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment', Clinical Cancer Research, vol. 16, no. 3, pp. 924-935. https://doi.org/10.1158/1078-0432.CCR-09-1486
Liang, Wei ; Kujawski, Maciej ; Wu, Jun ; Lu, Jianming ; Herrmann, Andreas ; Loera, Sofia ; Yen, Yun ; Lee, Frank ; Yu, Hua ; Wen, Wei ; Jove, Richard. / Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 3. pp. 924-935.
@article{cc701f0b9ed7494384eef3e82edd48b0,
title = "Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment",
abstract = "Purpose: Several Src family kinase (SFK) inhibitors have entered clinical trials based on their direct effects against tumor cells. Here, we characterize the effects of targeting Src kinases on the tumor micro-environment and how these effects influence tumor growth. Experimental Design: Human cancer cells grown in cell culture or in mice were treated with dasatinib, a small-molecule inhibitor of SFKs. Tumor cell, endothelial cell, and myeloid cell compartments within the tumor microenvironment were analyzed. Primary human endothelial cells and freshly isolated CD11b+/CD11c- myeloid cells from mice were treated with dasatinib in cell culture. Cellular functions and signaling pathways affected by dasatinib were evaluated. Results: Dasatinib was not cytotoxic in cell culture against the human cancer cell lines investigated here. However, dasatinib administration in human tumor-bearing mice suppressed tumor growth associated with increased tumor cell apoptosis, decreased microvessel density, and reduced intratumoral CD11b+ myeloid cells. Dasatinib directly inhibited motility and other functions of endothelial and myeloid cells, accompanied by the inhibition of phosphorylation of SFKs and downstream signaling. Tumor-infiltrating myeloid cells were identified as the major source of matrix metalloproteinase (MMP)-9 in the tumor microenvironment. Dasatinib treatment reduced MMP-9 levels in the tumor microenvironment through the simultaneous inhibition of recruitment of MMP9+ myeloid cells and MMP-9 gene expression in tumor-infiltrating myeloid cells. Conclusions: These findings suggest that Src kinase inhibitors such as dasatinib possess a previously unrecognized anticancer mechanism of action by targeting both host-derived endothelial and myeloid cell compartments within the tumor microenvironment.",
author = "Wei Liang and Maciej Kujawski and Jun Wu and Jianming Lu and Andreas Herrmann and Sofia Loera and Yun Yen and Frank Lee and Hua Yu and Wei Wen and Richard Jove",
year = "2010",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1486",
language = "English",
volume = "16",
pages = "924--935",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Antitumor activity of targeting Src kinases in endothelial and myeloid cell compartments of the tumor microenvironment

AU - Liang, Wei

AU - Kujawski, Maciej

AU - Wu, Jun

AU - Lu, Jianming

AU - Herrmann, Andreas

AU - Loera, Sofia

AU - Yen, Yun

AU - Lee, Frank

AU - Yu, Hua

AU - Wen, Wei

AU - Jove, Richard

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: Several Src family kinase (SFK) inhibitors have entered clinical trials based on their direct effects against tumor cells. Here, we characterize the effects of targeting Src kinases on the tumor micro-environment and how these effects influence tumor growth. Experimental Design: Human cancer cells grown in cell culture or in mice were treated with dasatinib, a small-molecule inhibitor of SFKs. Tumor cell, endothelial cell, and myeloid cell compartments within the tumor microenvironment were analyzed. Primary human endothelial cells and freshly isolated CD11b+/CD11c- myeloid cells from mice were treated with dasatinib in cell culture. Cellular functions and signaling pathways affected by dasatinib were evaluated. Results: Dasatinib was not cytotoxic in cell culture against the human cancer cell lines investigated here. However, dasatinib administration in human tumor-bearing mice suppressed tumor growth associated with increased tumor cell apoptosis, decreased microvessel density, and reduced intratumoral CD11b+ myeloid cells. Dasatinib directly inhibited motility and other functions of endothelial and myeloid cells, accompanied by the inhibition of phosphorylation of SFKs and downstream signaling. Tumor-infiltrating myeloid cells were identified as the major source of matrix metalloproteinase (MMP)-9 in the tumor microenvironment. Dasatinib treatment reduced MMP-9 levels in the tumor microenvironment through the simultaneous inhibition of recruitment of MMP9+ myeloid cells and MMP-9 gene expression in tumor-infiltrating myeloid cells. Conclusions: These findings suggest that Src kinase inhibitors such as dasatinib possess a previously unrecognized anticancer mechanism of action by targeting both host-derived endothelial and myeloid cell compartments within the tumor microenvironment.

AB - Purpose: Several Src family kinase (SFK) inhibitors have entered clinical trials based on their direct effects against tumor cells. Here, we characterize the effects of targeting Src kinases on the tumor micro-environment and how these effects influence tumor growth. Experimental Design: Human cancer cells grown in cell culture or in mice were treated with dasatinib, a small-molecule inhibitor of SFKs. Tumor cell, endothelial cell, and myeloid cell compartments within the tumor microenvironment were analyzed. Primary human endothelial cells and freshly isolated CD11b+/CD11c- myeloid cells from mice were treated with dasatinib in cell culture. Cellular functions and signaling pathways affected by dasatinib were evaluated. Results: Dasatinib was not cytotoxic in cell culture against the human cancer cell lines investigated here. However, dasatinib administration in human tumor-bearing mice suppressed tumor growth associated with increased tumor cell apoptosis, decreased microvessel density, and reduced intratumoral CD11b+ myeloid cells. Dasatinib directly inhibited motility and other functions of endothelial and myeloid cells, accompanied by the inhibition of phosphorylation of SFKs and downstream signaling. Tumor-infiltrating myeloid cells were identified as the major source of matrix metalloproteinase (MMP)-9 in the tumor microenvironment. Dasatinib treatment reduced MMP-9 levels in the tumor microenvironment through the simultaneous inhibition of recruitment of MMP9+ myeloid cells and MMP-9 gene expression in tumor-infiltrating myeloid cells. Conclusions: These findings suggest that Src kinase inhibitors such as dasatinib possess a previously unrecognized anticancer mechanism of action by targeting both host-derived endothelial and myeloid cell compartments within the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=76049104513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049104513&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1486

DO - 10.1158/1078-0432.CCR-09-1486

M3 - Article

C2 - 20103658

AN - SCOPUS:76049104513

VL - 16

SP - 924

EP - 935

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -